OPKO Health Q1 Loss Narrows to $54.8M While Regeneron Deal Tops $1B
OPKO posted Q1 net loss of $54.8 million, or $0.07 per share, an improvement from $67.6 million, or $0.10 per share a year earlier, with revenue below guidance due to BARDA contract delays. Its diagnostics segment targets breakeven by mid-year, and a Regeneron collaboration could generate more than $1 billion in milestones.
1. Q1 Financial Results
OPKO posted a net loss of $54.8 million, or $0.07 per share, improving from $67.6 million, or $0.10 per share a year earlier. First-quarter revenue fell below guidance due to delays in planned BARDA contract activities.
2. Diagnostics Business Restructuring
The diagnostics segment narrowed its operating loss to $30 million and is on track to achieve breakeven by mid-year following successful restructuring efforts.
3. Regeneron Collaboration Potential
The collaboration with Regeneron is advancing with potential total value exceeding $1 billion in milestone payments and future royalties, which could bolster OPKO's long-term revenue profile.
4. MODEX Pipeline and BARDA Outlook
OPKO’s MODEX pipeline includes five clinical programs across vaccines, oncology, and immunology, while BARDA-related activities remain delayed, pushing certain development timelines into the second quarter.